$290,000 of STRYKER CORPORATION lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. This ...

HUTCHMED announced positive results from the global Phase III SAFFRON trial, demonstrating that the combination of ORPATHYS® ...

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a ...

OpenWorld confirms its dual listing on Figure OPEN is set for Q4 2026, enhancing trading options for shareholders.

Reps. Zoe Lofgren and George Whitesides said they introduced the “SHIELD Our Elections Act,” a bill aimed at “protect[ing] ...

Rep. Steny Hoyer says he has asked the House and Senate Armed Services committees to investigate reports of restrictions on ...

Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial on October 26, 2026.

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization ...

NovaBridge Biosciences announced updated results from the Phase 1b study of givastomig, a bispecific antibody targeting ...

U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat: ...

ULTRALIFE lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. This included lobbying on ...

Pumitamig plus docetaxel demonstrated a confirmed objective response rate of 36.7% in patients with non-small cell lung ...